Refining the boundaries of resectability for colorectal cancer liver metastases with extrahepatic disease-surgical lessons from a nationwide analysis [0.03%]
来自全国范围分析的外科教训：对伴有肝外疾病的结直肠癌肝转移可切除边界的改进
Alexander S Thomas,Samer T Tohme,David A Geller
Alexander S Thomas
Rethinking nutritional risk in cancer: muscle quality, myosteatosis, and prognosis [0.03%]
重新思考癌症中的营养风险：肌肉质量、肌内脂肪和预后
Shangze Jiang,Haifeng Xu
Shangze Jiang
Takeshi Yamada,Kay Uehara,Hiroshi Yoshida
Takeshi Yamada
Precision transarterial chemoembolization in hepatocellular carcinoma: patient selection, standardized techniques, and quantitative evaluation [0.03%]
精准肝动脉化疗栓塞治疗肝细胞癌：患者选择、标准技术和量化评估
Bin-Yan Zhong,Zhongzhi Jia,Ho-Young Song et al.
Bin-Yan Zhong et al.
Transarterial chemoembolization (TACE) plays a critical role in the treatment of hepatocellular carcinoma (HCC), yet variability in its performance leads to inconsistent prognostic outcomes, with objective response rates (ORRs) ranging from...
Impact of metabolic dysfunction-associated steatotic liver disease on long-term prognosis in hepatocellular carcinoma patients undergoing hepatectomy [0.03%]
代谢功能异常相关性肝脂肪变性疾病对肝细胞癌患者术后长期预后的影响
Qingyan Kong,Jiahui Yang,Diao Kong et al.
Qingyan Kong et al.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) has been recognized as an accurate reflection of the pathogenesis of fatty liver disease by a consensus document. However, the relationship betw...
Pushing to resect colorectal liver metastases: rethinking surgical strategy in colorectal liver metastases with extrahepatic spread [0.03%]
结肠癌肝转移伴肝外扩散的手术策略再思考
Tor Magnus Smedman,Pål-Dag Line,Svein Dueland
Tor Magnus Smedman
Thomas M van Gulik
Thomas M van Gulik
Survival after resection of pancreatic cancer is similar with neoadjuvant gemcitabine-nab-paclitaxel or mFOLFIRINOX but one size will not fit all in the future [0.03%]
新辅助吉西他滨白蛋白结合型紫杉醇和mFOLFIRINOX治疗胰腺癌手术切除后的生存结局相似，但未来并不能一刀切
Sophia Hernandez,Ajay V Maker
Sophia Hernandez
Global benchmarks for robotic liver resection: Eastern excellence calls for reevaluation in the West [0.03%]
机器人肝脏切除的全球基准：东方卓越要求西方重新评估
Nagoud Schukfeh,Stefanie Langreen
Nagoud Schukfeh
Advancing risk stratification in intermediate-stage hepatocellular carcinoma undergoing transarterial chemoembolization: the promise of the NTAA model [0.03%]
推进经动脉化疗栓塞治疗的中度肝细胞癌风险分层：NTAA模型的前景
Zuzanna Kobus,Hooman Yarmohammadi
Zuzanna Kobus